Format

Send to

Choose Destination
Ann N Y Acad Sci. 2014 Sep;1323:101-14. doi: 10.1111/nyas.12444. Epub 2014 May 2.

Barriers to the effective treatment of sepsis: antimicrobial agents, sepsis definitions, and host-directed therapies.

Author information

1
Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, British Columbia, Canada.

Abstract

Sepsis is a complex clinical syndrome involving both infection and a deleterious host immune response. Antimicrobial agents are key elements of sepsis treatment, yet despite great strides in antimicrobial development in the last decades, sepsis continues to be associated with unacceptably high mortality (~30%). This is the result, on one hand, of the rise of antimicrobial resistant organisms and, on the other hand, of the dearth of effective host-directed immune therapies. A major obstacle to the development of good host-directed therapies is the lack of understanding of the host immune response. The problem is exacerbated by poor nonspecific clinical definitions of disease. Poor definitions have had a profound impact on sepsis research, from epidemiologic studies to the failed clinical trials of host-directed therapies. Therefore, better definitions must be developed to enable advancement in the field.

KEYWORDS:

antimicrobial resistance; host-directed therapies; immunology; sepsis; sepsis definitions

PMID:
24797961
DOI:
10.1111/nyas.12444
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center